On April 14, at the media center of "Rossiyskaya Gazeta", the press conference on import substitution in the field of medicine was held.

At the conference, Deputy Prime Minister, Minister of Investments and Innovations of Moscow Region, Denis Butsaev told about the great industrial potential of the region in order to implement the strategy of import substitution and development as a whole. According to the Minister of Investments and Innovations of the Moscow region, privileged conditions for industrial investors were established by the state, industrial sites were built with the primary infrastructure, and a system of taxation preferences was created. Special conditions will be established for the companies involved in high-tech production.

Due to these conditions, the suburban SEZ of technology-innovative type "Dubna" involved about 30 new residents over the past few years, and 12 more residents were attracted over the first quarter of 2016. The biomedical cluster in the "Dubna" is represented by the following companies: BEBIG - the first Russian producer of microsources for low-dose-rate brachytherapy, ARKRUS - producer of blood glucose meters and test strips, EYLITON - developer and manufacturer of equipment and consumables for clinical laboratory diagnostics.

Kirill Mayorov, Director General of BEBIG, told about the low-dose-rate brachytherapy market in Russia. “At the present moment we offer a full cycle production for manufacturing of the first domestic microsources for prostate brachytherapy, with a fully automated production line, which allows us to produce a product of high European quality,” - said Kirill Mayorov - “27 medical centers were opened, besides we have entered the market of Kazakhstan and Armenia. We are actively investing in the training of doctors, with the support of medical associations (Association of oncologists, Association of brachytherapists) and we provide Russian clinics with necessary clinical equipment. We also plan to get the "federal" status. Herewith we would like to open these medical centers for the treatment of prostate cancer in every region of the Russian Federation. We believe that the citizens of the Russian Federation have the same right to access high-tech medical care. At the present moment, we have produced more than 30 thousand microsources for brachytherapy, more than 500 operations with Russian sources were performed. Certainly, we want to get the full replacement of imported sources. We plan to accomplish this task by the end of 2016." In addition, the company plans export expansion. The centers have been already operating in Armenia and Kazakhstan; respective agreements were signed with Jordan, Iraq, Vietnam. There are arrangements with Korea.

 “We invest almost one hundred percent of our profits into the training of doctors, modernization of clinics and support of population screenings” - Director General of BEBIG Company precised. “Producing high-quality medical products, we strive to replace components to the Russian ones but only in terms of the highest quality and full compliance with our stringent requirements, we don’t accept any damping, as we are talking about lives of people. We are ready to compete. Our trump card is European quality of microsources, which we guarantee, and the best oncologists of the country are familiar with it.” According to Mayorov, the first and the only production of microspheres for liver cancer treatment is at the final stage of planning in Russia. “This is selective interstitial radiation therapy, which is required in treatment of liver cancer and is currently unique in the Russian Federation”, - shared Kirill Mayorov.


Photo: Alexander Korolkov / RG

Following “Rossiyskaya Gazeta”: